Moody's: Endo settlement is positive

Moody's Investors Service said that Endo Health Solutions Inc.'s patent settlement agreement with Watson Pharmaceuticals, Inc. is credit positive for Endo.

Endo has a Ba2 corporate family rating with a negative outlook.

"The agreement provides Endo with another 15 months of branded Lidoderm sales, avoiding more onerous scenarios," Moody's senior vice president Michael Levesque said in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.